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Abstract
Background: Previous studies suggest that the cyclooxygenase-2 (COX-2) inhibitor nimesulide has a remarkable
protective effect against different types of brain injury including ischemia. Since there are no reports on the effects of
nimesulide on permanent ischemic stroke and because most cases of human stroke are caused by permanent occlusion
of cerebral arteries, the present study was conducted to assess the neuroprotective efficacy of nimesulide on the cerebral
infarction and neurological deficits induced by permanent middle cerebral artery occlusion (pMCAO) in the rat.
Methods: Ischemia was induced by permanent occlusion of the middle cerebral artery in rats, via surgical insertion of a
nylon filament into the internal carotid artery. Infarct volumes (cortical, subcortical and total) and functional recovery,
assessed by neurological score evaluation and rotarod performance test, were performed 24 h after pMCAO. In initial
experiments, different doses of nimesulide (3, 6 and 12 mg/kg; i.p) or vehicle were administered 30 min before pMCAO
and again at 6, 12 and 18 h after stroke. In later experiments we investigated the therapeutic time window of protection
of nimesulide by delaying its first administration 0.5–4 h after the ischemic insult.
Results: Repeated treatments with nimesulide dose-dependently reduced cortical, subcortical and total infarct volumes
as well as the neurological deficits and motor impairment resulting from permanent ischemic stroke, but only the
administration of the highest dose (12 mg/kg) was able to significantly (P < 0.01) diminish infarct volume. The lower doses
failed to significantly reduce infarction but showed a beneficial effect on neurological function. Nimesulide (12 mg/kg) not
only reduced infarct volume but also enhanced functional recovery when the first treatment was given up to 2 h after
stroke.
Conclusions: These data show that nimesulide protects against permanent focal cerebral ischemia, even with a 2 h post-
treatment delay. These findings have important implications for the therapeutic potential of using COX-2 inhibitors in
the treatment of stroke.
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Background
The brain is highly sensitive to disturbance of its blood
supply. Stroke is a devastating disease and is the third
most common cause of death, and the most common
cause of motor and mental disability in adults, in devel-
oping countries [1]. Complex pathophysiological events
occur in brain during ischemic processes, and these are
considered responsible for cell damage leading to neuro-
nal death (for review see [2,3]). However, it is now gener-
ally accepted that the mammalian brain may be more
resistant to ischemia than previously thought. This raises
the possibility of therapeutic intervention before brain
damage has become irreversible.
A number of interacting and sequentially evoked events
tend to reinforce the initial ischemic insult. A key role in
these processes is played by post-ischemic inflammation.
The Ca2+-related activation of intracellular second mes-
senger systems, the increase in reactive oxygen species for-
mation, as well as hypoxia itself triggers the expression of
a large number of pro-inflammatory genes following cer-
ebral ischemia. Thus, mediators of inflammation such as
platelet-activating factor (PAF), tumor necrosis factor α
(TNFα), interleukin 1β (IL-1β), chemokines (IL-8, mono-
cyte chemoattractant protein-1) and other pro-inflamma-
tory factors are produced by the ischemic brain tissue [3].
In addition, the expression of adhesion molecules with
the subsequent infiltration of polymorphonuclear leuko-
cytes occurs following ischemic stroke. Results from sev-
eral studies also suggest that the marked and sustained
expression of inflammation-related enzymes such as
inducible nitric oxide synthase (iNOS) and cyclooxygen-
ase-2 (COX-2) plays an important role in the secondary
events that amplify cerebral injury after ischemia [4-12].
Nimesulide (N-(4-nitro-2-phenoxyphenyl)-methanesul-
fonamide) is a non-steroidal anti-inflammatory drug with
potent effects. It shows a high affinity and selectivity for
COX-2 with a COX-2/COX-1 IC50 selectivity ratio of 0.06
(whole blood assay) [13]. Nimesulide readily crosses the
intact blood-brain barrier in both humans and rodents
[13,14]. Several recent studies have demonstrated a
marked neuroprotective effect of nimesulide on chronic
cerebral hypoperfusion [15], kainate-induced excitotoxic-
ity [16], quisqualic acid-induced neurodegeneration [17],
diffuse traumatic brain injury [18,19], glutamate-medi-
ated apoptotic damage [20] and induction of the expres-
sion of the B subunit of endogenous complement
component C1q (C1qB) in transgenic mice with neuronal
overexpression of human COX-2 [21].
Recently, we have found a significant neuroprotective
effect of nimesulide both in global cerebral ischemia
[10,22], a type of injury that mimics the clinical situation
of cardio-respiratory arrest, and in a rat model of ischemic
stroke induced by the transient (1 h) occlusion of the mid-
dle cerebral artery [12].
Since most cases of human ischemic stroke are caused by
permanent occlusion of cerebral arteries [23-26], the
present study was conducted to assess whether nimesulide
would also show neuroprotective efficacy on the cerebral
infarction induced by permanent middle cerebral artery
occlusion (pMCAO) in the rat, a clinically relevant model
of ischemic stroke. The effects of the COX-2 inhibitor
nimesulide had not been previously investigated in a
model of permanent ischemic stroke.
Methods
Animals
Male Sprague-Dawley rats (CENPALAB, Havana, Cuba)
weighing 280–340 g at the time of surgery were used in
the present study. Our institutional animal care and use
committee approved the experimental protocol (No. 02/
67). The animals were quarantined for at least 7 days
before the experiment. Animals were housed in groups in
a room whose environment was maintained at 21–25°C,
45–50 % humidity and 12-h light/dark cycle. They had
free access to pellet chow and water. Animal housing, care,
and application of experimental procedures were in
accordance with institutional guidelines under approved
protocols.
Induction of permanent focal cerebral ischemia in the rat
Rats were anesthetized with chloral hydrate (300 mg/kg
body weight, i.p.). Once surgical levels of anesthesia were
attained (assessed by absence of hind leg withdrawal to
pinch), ischemia was induced by using an occluding intra-
luminal suture as described previously [27-29]. Briefly,
the right common carotid artery (CCA) was exposed by a
ventral midline neck incision and ligated with a 3-0 silk
suture. The pterygopalatine branch of the internal carotid
artery was clipped to prevent incorrect insertion of the
occluder filament. Arteriotomy was performed in the CCA
approximately 3 mm proximal to the bifurcation and a 3-
0 monofilament nylon suture, whose tip had been
rounded by being heated near a flame was introduced into
the internal carotid artery (ICA) until a mild resistance
was felt (18–19 mm). Mild resistance to this advancement
indicated that the intraluminal occluder had entered the
anterior cerebral artery and occluded the origin of the
anterior cerebral artery, the middle cerebral artery (MCA)
and posterior communicating arteries [27]. After the
advancement of the nylon suture, the ICA was firmly
ligated with a 3-0 silk suture. The incision was closed and
the occluding suture was left in place until sacrificing the
animals. The duration of surgery did not exceed 12 min in
any case. The animals were allowed to recover from
anesthesia and to eat and drink freely. The body tempera-
ture was strictly controlled during and after ischemia. ToJournal of Neuroinflammation 2005, 2:3 http://www.jneuroinflammation.com/content/2/1/3
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allow for better postoperative recovery, we chose not to
monitor physiological parameters in the present study
because additional surgical procedures are needed for this
monitoring. Nevertheless, we performed separate experi-
ments to investigate the effects of nimesulide on major
physiological variables such as mean arterial blood pres-
sure, blood glucose, rectal temperature, hematocrit, blood
pH and blood gases (pO2 and pCO2). The effects observed
with nimesulide in the present study were not related to
modification of physiological variables since these param-
eters did not differ between nimesulide-treated and vehi-
cle-treated rats (data not shown). These findings are in
agreement with our previous results [10,12], suggesting
that nimesulide does not significantly change major phys-
iological variables.
Neurological evaluation
An unaware independent observer performed the neuro-
logical evaluations prior to the sacrifice of the animals
according to a six-point scale: 0= no neurological deficits,
1= failure to extend left forepaw fully, 2= circling to the
left, 3= falling to left, 4= no spontaneous walking with a
depressed level of consciousness, 5= death [30,31].
Assessment of functional outcome
Motor impairment in this study was assessed with the use
of the accelerating rotarod (Ugo Basile, Varese, Italy,
Model 7750). Rats were given 2 training sessions 10 min-
utes apart before surgery. Rats were first habituated to the
stationary rod. After habituation they were exposed to the
rotating rod. The rod was started at 2 rpm and accelerated
linearly to 20 rpm within 300 sec. Latency to fall off the
rotarod was then determined before ischemia (presur-
gery) and before sacrificing the animals. Animals were
required to stay on the accelerating rod for a minimum of
30 sec. If they were unable to reach this criterion, the trial
was repeated for a maximum of five times. The two best
(largest) fall latency values a rat could achieve then were
averaged and used for data analysis. Rats not falling off
within 5 min were given a maximum score of 300 seconds
[32,33]. A sham-operated group was also included (n =
8). The investigator performing the rotarod test did not
know the identity of the experimental groups until com-
pletion of data analysis.
Quantification of brain infarct volume
The method for quantification of infarct volume was per-
formed exactly as reported by others [34,35]. Briefly, the
animals were sacrificed under deep anesthesia and brains
were removed, frozen, and coronally sectioned into six 2-
mm-thick slices (from rostral to caudal, first to sixth). The
brain slices were incubated for 30 min in a 2% solution of
2,3,5-triphenyltetrazolium chloride (TTC) (Sigma Chem-
ical Co.) at 37°C and fixed by immersion in a 10% phos-
phate-buffered formalin solution. Six TTC-stained brain
sections per animal were placed directly on the scanning
screen of a color flatbed scanner (Hewlett Packard HP
Scanjet 5370 C) within 7 days. Following image acquisi-
tion, the image were analyzed blindly using a commercial
image processing software program (Photoshop, version
7.0, Adobe Systems; Mountain View, CA). Measurements
were made by manually outlining the margins of infarcted
areas. The unstained area of the fixed brain section was
defined as infarcted. Cortical and subcortical uncorrected
infarcted areas and total hemispheric areas were calcu-
lated separately for each coronal slice. Total cortical and
subcortical uncorrected infarct volumes were calculated
by multiplying the infarcted area by the slice thickness
and summing the volume of the six slices. A corrected inf-
arct volume was calculated to compensate for the effect of
brain edema. An edema index was calculated by dividing
the total volume of the hemisphere ipsilateral to pMCAO
by the total volume of the contralateral hemisphere. The
actual infarct volume adjusted for edema was calculated
by dividing the infarct volume by the edema index [36-
38]. Infarct volumes are expressed as a percentage of the
contralateral (control) hemisphere. The investigators who
performed the image analysis were blinded to the study
groups.
Experimental design
Time course of lesion development after pMCAO
At various times after pMCAO (4, 8, 12, 24 and 48 h, n =
6–8 per group) the animals were sacrificed and the brains
were quickly removed, sectioned and stained as previ-
ously described in order to calculate the infarct volume.
Evaluation of nimesulide's effects: dose-response 
experiment
In order to evaluate the effect of nimesulide administra-
tion on rat focal cerebral ischemia, three different doses of
nimesulide (3, 6 and 12 mg/kg) were given to rats by
intraperitoneal administration 30 min before the onset of
pMCAO (n = 7–9 animals per group). Additional doses
were given at 6, 12 and 18 h after stroke. This treatment
schedule and dosage range was based on the pharmacok-
inetic profile of nimesulide [39] and on our previous
experience with this compound in models of cerebral
ischemia [10,12]. We also studied the effect of a single
dose of nimesulide (12 mg/kg; i.p.) given 30 min before
ischemia (n = 8). A single injection vehicle-treated group
was also included (n = 7).
Assessment of the therapeutic time window for the 
neuroprotective effect of nimesulide in pMCAO
After investigating the dose-response relationship, we
studied the effect of nimesulide (12 mg/kg; i.p.) when
administered 0.5, 1, 2, 3 or 4 h after ischemia (n = 8–11
animals per group). The corresponding vehicle-treated
groups were included as controls (n = 7–10 rats perJournal of Neuroinflammation 2005, 2:3 http://www.jneuroinflammation.com/content/2/1/3
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group). Three additional doses were given every 6 h after
the first treatment with nimesulide or vehicle exactly as
described before for the repeated treatment schedule in
the dose-response experiment. After completing the neu-
rological evaluation and rotarod performance at 24 h after
permanent focal cerebral ischemia, animals were sacri-
ficed and the brains were removed to calculate the infarct
size.
Data analysis
Data are presented as means ± S.D. Values were compared
using t-test (two groups) or one-way ANOVA with post-hoc
Student-Newman-Keuls test (multiple comparison). Neu-
rological deficit scores were analyzed by Kruskal-Wallis
non-parametric ANOVA followed by the Dunn test (mul-
tiple comparison) or Mann-Whitney test for analysis of
individual differences. Rotarod performance was
expressed as a percentage of pre-surgery values for each rat
and analyzed by ANOVA for repeated measures followed
by the Student-Newman-Keuls test. Differences were con-
sidered significant when p < 0.05.
Results
Time course of the development of cerebral infarction and 
neurological deficits after pMCAO
The temporal evolution of the lesion volumes is presented
in Fig. 1A as the cortical and subcortical components of
the infarction. Subcortical injury was evident in TTC-
stained coronal sections as early as 4 h after permanent
stroke (see insets of TTC-stained sections at different times
after stroke in Fig. 1A). Subcortical lesion was maximal
between 8 and 12 h after pMCAO, although there was a
slight but significant increase between 8 and 24 h when
the overall comparison was performed (one-way ANOVA,
followed by Student-Newman-Keuls test). Nevertheless,
the Student's t-test analysis failed to detect any significant
increase between 12 and 24 or 48 h post-injury, thus indi-
cating that the subcortical damage reached maximal val-
ues by 12 h after the insertion of the occluding filament
(Fig. 1A). On the other hand, cortical damage progressed
more slowly; it was detected at 4 h after pMCAO, and by
8 h there was an increase of the infarct but this was not sta-
tistically significant as compared to that at 4 h. On the
contrary, there was a significant (p < 0.05) increase in the
lesion when the infarction at 12 h is compared with that
at 4 or 8 h, and a more dramatic increase of damage is seen
at 24–48 h after stroke, a time at which the cortical infarct
volume is maximal in this model as shown in Fig. 1A.
With regard to the neurological deficits and motor impair-
ment induced by pMCAO (assessed by the neurological
score and accelerating rotarod test), it is important to
emphasize the fact that these parameters were maximal by
12 h after stroke and the animals did not show any further
increase in the neurological deficits or motor impairment
after 24 or 48 h of the occlusion, as depicted in Fig. 1B and
Fig. 1C. Based on these results, we decided to evaluate the
effects of nimesulide after 24 h of pMCAO.
Effects of different doses of nimesulide on infarct volume 
and functional outcome after pMCAO
Repeated treatments with nimesulide dose-dependently
reduced cortical, subcortical and total infarct volumes in
the permanent model of stroke, although only the admin-
istration of the highest dose (12 mg/kg) was able to signif-
icantly (P < 0.01) diminish brain damage (Table 1). There
was a trend towards a reduction in lesion volumes in ani-
mals treated with nimesulide 6 mg/kg, but this effect was
not confirmed by the statistical analysis of the data.
Unlike the long-term treatment paradigm, the administra-
tion of a single dose of nimesulide (12 mg/kg) 30 min
before pMCAO failed to significantly reduce total infarct
volume, though a modest neuroprotective effect was seen
in the subcortical areas as shown in Table 1.
Interestingly, repeated treatments with 6 and 12 mg/kg of
nimesulide were similarly effective in reducing the neuro-
logical deficits and the motor impairment resulting from
pMCAO (Table 2). This effect was not accompanied by a
significant reduction in infarct volume in the case of the
dose of 6 mg/kg (Table 1). No neuroprotective effect of
nimesulide was observed on the neurological score or
rotarod performance when this COX-2 inhibitor was
administered as a single dose (12 mg/kg) before the onset
of ischemia (Table 2).
Therapeutic time window for nimesulide protection in rats 
subjected to pMCAO
In this experiment we investigated the effect of nimesulide
(12 mg/kg) in a situation in which its first administration
was delayed for 0.5–4 h after the ischemic challenge. A sig-
nificant reduction in subcortical infarct volume was
observed when the treatment was delayed until 0.5–1 h
after pMCAO, but this protective effect of nimesulide was
not evident when administered after 2–4 h of the onset of
permanent occlusion (Fig. 2A). In the case of cortical inf-
arction, nimesulide diminished lesion volume when
treatment was delayed until 2 h after the ischemic insult
(Fig. 2B). Similar results were found for total infarct vol-
ume as shown in Fig. 2C, though as expected, an overall
decline of the neuroprotective effect with post-treatment
time was observed.
Of interest is the finding that nimesulide not only reduced
infarct volume but also enhanced functional recovery
when the first treatment is given 2 h after permanent
ischemic stroke. Post-ischemic treatment with nimesulide
significantly reduced neurological deficits and increased
the fall latencies to remain on the accelerating rotarod as
compared to those rats given only the vehicle (Table 3).Journal of Neuroinflammation 2005, 2:3 http://www.jneuroinflammation.com/content/2/1/3
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Temporal development of focal cerebral infarction induced by permanent middle cerebral artery occlusion (pMCAO) Figure 1
Temporal development of focal cerebral infarction induced by permanent middle cerebral artery occlusion (pMCAO). (A): 
Evolution of cortical and subcortical infarct volumes after pMCAO in rats. Representative TTC-stained sections at different 
times after stroke are shown in the insets. (B) and (C): Time course of the increase of neurological deficits and motor impair-
ment induced by pMCAO. Infarct volumes are expressed as a percentage of the contralateral (control) hemisphere. Bars rep-
resent the group mean ± SD. * p < 0.05 with respect to subcortical infarct volume at 4 h. &p < 0.05 with respect to subcortical 
infarct volume at 8 h. # p < 0.05 with respect to cortical infarct volume at 8 h. ** p < 0.05 with respect to cortical infarct vol-
ume at 12 h. § p < 0.05 with respect to 4 and 8 h. The horizontal bar in Panel B shows the median neurological score.
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However, this protective effect was lost when the first
administration is delayed until 3–4 h after the occlusion
of the middle cerebral artery as presented in Table 3.
Discussion
The present study was prompted by our previous encour-
aging results with nimesulide in a model of transient focal
cerebral ischemia, which show that this COX-2 inhibitor
is able to potently reduce infarct volume and improve
functional recovery [12]. These neuroprotective effects are
also observed when treatment is delayed until even 24 h
after the onset of ischemia [12]. Since we believe that it is
very important to perform thorough, multifactorial and
well-designed pre-clinical studies before assuming defini-
tive conclusions on the neuroprotective effect of any com-
pound, and considering that in stroke patients a very early
spontaneous recanalization of an obstructed brain vessel
is, unfortunately, only rarely found, we conducted the
present investigation to shed more light into the effects of
nimesulide on ischemic damage using a permanent stroke
model in the rat considering that this model might be
more relevant to the clinical situation of stroke, as sug-
gested previously [23-26].
The core findings of this study are: (i) administration of
clinically relevant doses of nimesulide confers protection
against the damage induced by permanent focal cerebral
ischemia in two modalities (reduction of infarct size, and
improvement of functional outcome) and (ii)
Table 1: Effect of different doses of the cyclooxygenase-2 inhibitor nimesulide on total, cortical and subcortical infarct volumes in a rat 
model of permanent focal cerebral ischemia.
Treatment Total infarct volume (%) Cortical infarct volume (%) Subcortical infarct volume (%)
Repeated doses
Vehicle (n = 9) 56.1 ± 11.4 41.6 ± 10.3 12.6 ± 4.5
Nimesulide 3 mg/kg (n = 7) 54.9 ± 14.9 38.1 ± 17.2 14.3 ± 2.4
Nimesulide 6 mg/kg (n = 8) 41.4 ± 12.3 31.8 ± 9.3 9.7 ± 3.5
Nimesulide 12 mg/kg (n = 9) 34.1 ± 13.8 ** 24.6 ± 11.2 ** 7.1 ± 3.9 *
Single dose
Vehicle, single dose (n = 7) 55.2 ± 15.5 43.9 ± 10.9 13.2 ± 4.2
Nimesulide 12 mg/kg, single dose 
(n = 8)
49.5 ± 11.7 39.4 ± 11.8 9.1 ± 3.1&
Data are mean ± S.D. * P < 0.05 and ** P < 0.01 compared to vehicle. One-way ANOVA followed by Student-Newman-Keuls post-hoc test. &P < 
0.05 compared to vehicle single dose (Student's t-test).
Table 2: Effect of different doses of nimesulide on neurological deficits and functional outcome (evaluated using the rotarod test) 
following permanent middle cerebral artery occlusion in the rat.
Treatment Neurological Score Rotarod performance (% of presurgery 
levels)
Sham-operated control (n = 8) 0 128 ± 21
Repeated doses
Vehicle (n = 9) 3 (3–5) 49 ± 18
Nimesulide 3 mg/kg (n = 7) 3 (2–4) 64 ± 13
Nimesulide 6 mg/kg (n = 8) 2 (1–5) * 89 ± 20 **
Nimesulide 12 mg/kg (n = 9) 2 (1–4) ** 84 ± 14 **
Single dose
Vehicle, single dose (n = 7) 3 (3–5) 43 ± 21
Nimesulide 12 mg/kg, single dose (n = 8) 3.5 (2–5) 52 ± 19
Values show the median and range (neurological score) and means ± S.D. (rotarod performance). For the analysis of neurological score data, the 
Kruskal-Wallis nonparametric ANOVA followed by Dunn test (multiple comparison) or Mann-Whitney test for analysis of individual differences 
were used. For the statistical analysis of rotarod performance results, ANOVA followed by Student-Newman-Keuls post-hoc test was employed. * 
P < 0.05 and ** P < 0.01 compared to vehicle.Journal of Neuroinflammation 2005, 2:3 http://www.jneuroinflammation.com/content/2/1/3
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Reduction of subcortical (A), cortical (B) and total (C) infarct volumes by the cyclooxygenase-2 inhibitor nimesulide (12 mg/kg;  i.p.) when its first administration was delayed for several hours after the onset of permanent stroke Figure 2
Reduction of subcortical (A), cortical (B) and total (C) infarct volumes by the cyclooxygenase-2 inhibitor nimesulide (12 mg/kg; 
i.p.) when its first administration was delayed for several hours after the onset of permanent stroke. Nimesulide reduced the 
infarct size in animals treated at 0.5 (n = 8), 1 (n = 9) and 2 h (n = 9), but not at 3 (n = 11) and 4 h (n = 9) after pMCAO, com-
pared to vehicle-treated and time-comparable control groups (n = 7–9 per group). Infarct volumes are expressed as a percent-
age of the contralateral (control) hemisphere and the data are represented as the mean ± SD. * p < 0.05 and ** p < 0.01 with 
respect to vehicle (Student's t-test).
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nimesulide's neuroprotection is still evident when the first
administration is delayed until 2 h after the onset of
stroke.
Depending on the experimental conditions, the temporal
evolution of ischemic damage may vary considerably
[30,40,41]. Thus, it is very important to characterize the
time course of brain damage, especially if one wants to
interpret correctly the effects of a given compound using
delayed treatment schedules. Our results showed that in
the permanent model of stroke induced by the occlusion
of the middle cerebral artery using an intraluminal suture,
the infarct size progresses very fast in the subcortical areas
(mainly striatum) and much slower in cortical areas, but
in general the evolution of damage is relatively quick,
reaching maximal values by 24 h after the insertion of the
filament (Fig. 1A). These findings are in line with those
published previously in this model of stroke [42,43].
Although infarct size continues to increase between 12
and 24–48 h of ischemia (Fig. 1A), the neurological defi-
cits and motor impairment reached their maximum by 12
h, and the animals did not showed any further deteriora-
tion of their neurological functions (Fig. 1B and 1C). This
might reflect the fact that unlike ischemic injury to many
other tissues, the severity of disability is not predicted well
by the amount of brain tissue lost. For example, damage
to a small area in the medial temporal lobe may lead to
severe disability, while damage to a greater volume else-
where has little effect on function [2]. There is not always
a direct correlation between the lesion size and the sever-
ity of neurological deficits as demonstrated before in ani-
mal models [29,44] and in stroke patients [45]. For that
reason, it is essential to evaluate the neuroprotective
effects of agents by combining both histological and func-
tional measures. The present study offers a good example
of this: even when the lowest doses of nimesulide did not
reduce infarct volume in pMCAO (Table 1), one can not
minimize the beneficial effects of these doses since a sig-
nificant reduction in neurological deficits and an
improvement of rotarod performance were observed
(Table 2). Thus, further studies would be required to bet-
ter characterize the effects of the lowest doses of
nimesulide (3 and 6 mg/kg) in models of cerebral
ischemia.
Repeated treatments with nimesulide afforded a more
remarkable neuroprotection than the administration of a
single dose given before the insult (Tables 1 and 2). These
data show the importance of continuous long-term
administration after ischemic damage in clinical trials to
achieve the maximal beneficial effects of neuroprotection
by nimesulide.
Unfortunately, a large number of promising neuroprotec-
tive compounds identified from preclinical experiments
have failed in clinical trials in stroke patients [3,45-47].
Although several factors may contribute to these disap-
pointing results, an important issue is the 'therapeutic
time window of protection', defined as the time period
after the onset of ischemia during which administration
of treatment is effective [48,49]. Most of the agents that
confer protection in experimental animal models of
stroke when given before or a short period after cerebral
ischemia have failed in clinical studies [45,50]. Thus, the
assessment of the therapeutic time window of protection
is of paramount importance in pursuing future therapies
to treat stroke victims.
Therefore, our next experiments were conducted to evalu-
ate the effects of nimesulide when administered in a
delayed treatment schedule in order to establish the ther-
apeutic time window of protection of this COX-2 inhibi-
tor in pMCAO, thus increasing predictive outcome in the
clinic. Interestingly, reduction in infarct size and neuro-
Table 3: Effect of delayed administration of nimesulide (12 mg/kg; i.p.) on neurological deficit score and rotarod performance after 
permanent middle cerebral artery occlusion (pMCAO) in rats. Vehicle or nimesulide was administered 0.5, 1, 2, 3, or 4 h after stroke.
Neurological Score Rotarod performance (%)
Time after stroke (h) Vehicle Nimesulide Vehicle Nimesulide
0.5 3 (2–5) 2 (1–3) ** 44 ± 17 81 ± 18 **
1 3 (2–5) 2 (1–4) ** 40 ± 21 85 ± 22 **
2 3 (3–5) 2 (1–5) * 50 ± 11 73 ± 13 *
3 3 (2–5) 3 (2–5) 47 ± 16 60 ± 15
4 3.5 (2–5) 3 (2–5) 52 ± 23 59 ± 14
Values represent the median and range (neurological score) and means ± S.D. (rotarod performance). *P < 0.05 and **P < 0.01 compared with the 
corresponding vehicle-treated group.Journal of Neuroinflammation 2005, 2:3 http://www.jneuroinflammation.com/content/2/1/3
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logical deficits and improvement of rotarod performance
were still observed when nimesulide treatment was
delayed until 2 h after ischemia (Fig. 2A, Table 3).
It is important to compare our present results in pMCAO
with those previously obtained in transient ischemia [12].
In the model of transient focal ischemia, the time window
of nimesulide's neuroprotection extends over a 24 h
period [12], and in other models of cerebral ischemia, the
time window of protection of nimesulide is similarly wide
[10,22,51]. These results have been also obtained with
other COX-2 inhibitors (e.g., NS-398, SC58125 and
rofecoxib) in models of transient ischemic stroke [4,52]
and global cerebral ischemia [53,54]. These studies
suggest that although the protective effects of COX-2
inhibitors are more beneficial when administered early
after the ischemic insult, COX-2 selective inhibitors show
a wide therapeutic window for the prevention of neuronal
death in both focal and global ischemia.
However, our present results suggest that in permanent
stroke, COX-2 inhibition by nimesulide is not as protec-
tive as in transient models (39 % of infarct reduction with
pre-treatment in pMCAO vs. 60 % lesion reduction in
transient ischemia with immediate treatment) and the
therapeutic time window is narrower as compared to tem-
porary occlusion models (2 h in pMCAO vs. 24 h in tran-
sient ischemia) as the present results (Tables 1 and 3, Fig.
2) and our recent studies indicate [12]. The vascular inac-
cessibility of nimesulide into the ischemic/infarcted
region could be a plausible explanation for these findings
considering that, unlike transient ischemia, in permanent
ischemic stroke the protective effects of any drug/agent
depend, in large part, on the ability of the compound to
reach the ischemic areas mainly through passive diffu-
sion. Although these findings on nimesulide's effects on
stroke tempted us to conclude that COX-2 selective inhib-
itors are less protective in permanent than in transient
stroke models, these results should be interpreted with
caution since a structurally similar COX-2 inhibitor (NS-
398) reduced permanent stroke damage in mice when the
treatment started 24 h after MCA occlusion [55] and the
same COX-2 inhibitor also reduced lesion size when
administered starting 6 h after pMCAO in another previ-
ous study [5]. Apparent discrepancies between our present
results and these two reports [5,55] might be due to differ-
ent methods to induce pMCAO (intraluminal vs. distal
MCAO involving craniectomy), the specific COX-2 inhib-
itor used, treatment paradigm or animal species. This
emphasizes the importance of conducting more preclini-
cal studies with COX-2 selective inhibitors before these
agents could be used in clinical trials in stroke patients.
Another issue that needs urgent consideration in future
studies with COX-2 inhibitors in cerebral ischemia is the
effect of long-term treatment since anti-inflammatory
interventions could interfere with nervous regeneration/
plasticity and recovery as demonstrated in some types of
neuronal injury [56,57].
Conclusion
In summary, the present study has evaluated for the first
time the neuroprotective effects of the COX-2 inhibitor
nimesulide in permanent focal cerebral ischemia, show-
ing beneficial effects on reduction of infarct volume and
improvement of functional recovery. This ability of
nimesulide to diminish permanent ischemic damage is
observed even when the first treatment was delayed 2 h
after the ischemic episode. Taken together, these results
have important implications for the therapeutic potential
of using the COX-2 selective inhibitor nimesulide in the
treatment of cerebral ischemia.
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